You are not logged in.

E-cadherin aptamer-conjugated delivery of doxorubicin for targeted inhibition of prostate cancer cells

Chaudhary, Resham, Roy, Kislay, Kanwar, Rupinder K., Veedu, Rakesh N., Krishnakumar, Subramanian, Cheung, Chun Hei Antonio, Verma, Anita K. and Kanwar, Jagat R. 2016, E-cadherin aptamer-conjugated delivery of doxorubicin for targeted inhibition of prostate cancer cells, Australian journal of chemistry, vol. 69, no. 10, pp. 1108-1116, doi: 10.1071/CH16211.

Attached Files
Name Description MIMEType Size Downloads

Title E-cadherin aptamer-conjugated delivery of doxorubicin for targeted inhibition of prostate cancer cells
Author(s) Chaudhary, Resham
Roy, Kislay
Kanwar, Rupinder K.
Veedu, Rakesh N.
Krishnakumar, Subramanian
Cheung, Chun Hei Antonio
Verma, Anita K.
Kanwar, Jagat R.
Journal name Australian journal of chemistry
Volume number 69
Issue number 10
Start page 1108
End page 1116
Total pages 9
Publisher CSIRO
Place of publication Clayton, Vic.
Publication date 2016-08-24
ISSN 0004-9425
1445-0038
Keyword(s) Science & Technology
Physical Sciences
Chemistry, Multidisciplinary
Chemistry
Summary Regardless of the tremendous effort to develop an effective therapeutic approach to combat prostate cancer, target-specific therapy without adverse side effects on healthy tissues and cells is yet to be achieved. Triggered by this craving, we herein report the synthesis of algal chitosan nanoparticles containing DNA aptamer-targeting E-cadherin (Ecad01) using an ionotropic gelation method for target-specific delivery of doxorubicin (Dox) to inhibit prostate cancer cell (DU145) proliferation. The designed chimeric Ecad01-Dox conjugate exhibited excellent targeted internalization, which was evident from a 1.71-fold-increased internalization in DU145 cells, and showed significantly lower uptake (1.92-fold lower) in non-cancerous cells (RWPE-1). Moreover, cell viability assay results showed that 1.0M Dox in the Ecad01-Dox conjugate was able to show similar cytotoxicity to 10M Dox in DU145 cells, which is indicative of targeted cancer-specific inhibition. Our study clearly demonstrated that encapsulation of Ecad01-Dox conjugate in algal chitosan increased its cellular uptake to 58% in 30min, with reduced non-specific cytotoxicity and enhanced chemotherapeutic potential. This could be a simple and an effective targeted drug-delivery strategy that does not require chemical modification of the doxorubicin or the Ecad01 aptamer with potential in developing a therapeutic agent for prostate cancer.
Language eng
DOI 10.1071/CH16211
Field of Research 111201 Cancer Cell Biology
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, The Authors
Persistent URL http://hdl.handle.net/10536/DRO/DU:30089605

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in TR Web of Science
Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 25 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Tue, 07 Mar 2017, 10:40:19 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.